Boston Common Asset Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$28M Buy
24,195
+1,638
+7% +$1.93M 1.62% 12
2026
Q2
$27.1M Sell
22,557
-1,796
-7% -$1.84M 1.6% 12
2026
Q1
$22.4M Sell
24,353
-2,875
-11% -$2.91M 1.44% 14
2025
Q4
$29.3M Sell
27,228
-8,064
-23% -$7.71M 1.76% 11
2025
Q3
$26.9M Sell
35,292
-471
-1% -$350K 0.75% 35
2025
Q2
$27.9M Buy
35,763
+8,468
+31% +$6.58M 0.78% 36
2025
Q1
$22.5M Buy
27,295
+3,267
+14% +$2.72M 0.68% 46
2024
Q4
$18.5M Buy
24,028
+5,465
+29% +$4.53M 0.54% 67
2024
Q3
$16.4M Buy
18,563
+8,106
+78% +$7.29M 0.43% 91
2024
Q2
$9.47M Buy
10,457
+600
+6% +$480K 0.24% 128
2024
Q1
$7.67M Sell
9,857
-247
-2% -$176K 0.18% 155
2023
Q4
$5.89M Sell
10,104
-287
-3% -$168K 0.13% 189
2023
Q3
$5.58M Buy
10,391
+4,253
+69% +$2.19M 0.13% 186
2023
Q2
$2.88M Buy
+6,138
New +$2.57M 0.06% 236
2023
Q1
– Sell
-2,825
Closed -$1.03M – 331
2022
Q4
$1.03M Buy
2,825
+66
+2% +$23.4K 0.05% 162
2022
Q3
$892K Buy
2,759
+35
+1% +$11.1K 0.05% 167
2022
Q2
$883K Buy
2,724
+233
+9% +$69.9K 0.04% 178
2022
Q1
$713K Sell
2,491
-298
-11% -$76.7K 0.03% 189
2021
Q4
$770K Buy
2,789
+151
+6% +$38.3K 0.03% 185
2021
Q3
$610K Buy
2,638
+6
+0.2% +$1.48K 0.03% 198
2021
Q2
$604K Buy
2,632
+185
+8% +$37.2K 0.03% 204
2021
Q1
$457K Buy
2,447
+27
+1% +$5.28K 0.03% 212
2020
Q4
$409K Buy
+2,420
New +$361K 0.03% 209

Other funds holding LLY

Boston Common Asset Management's LLY Position: Q3 2026 in Review

Boston Common Asset Management increased its Eli Lilly (LLY) stake by 7.3% in Q3 2026, buying an estimated $1.93M and bringing the position to 24,195 shares worth $28M. The position accounts for 1.62% of the portfolio, ranked #12.

Boston Common Asset Management first reported a position in LLY in Q4 2020 and has held it in 23 quarters since. The position peaked at $29.3M in Q4 2025. 565 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Boston Common Asset Management held 24,195 shares of Eli Lilly worth $28M as of Q3 2026.
  • Boston Common Asset Management bought 1,638 Eli Lilly shares in Q3 2026, an estimated $1.93M.
  • Eli Lilly made up 1.62% of Boston Common Asset Management's portfolio in Q3 2026, its #12 holding.
  • Boston Common Asset Management first reported a position in Eli Lilly in Q4 2020 and has held it in 23 quarters since.
  • Boston Common Asset Management's Eli Lilly position peaked at $29.3M in Q4 2025.
  • 565 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Boston Common Asset Management's 13F filing for Q3 2026, filed 13 Oct 2026.